CYP51A1 and lung carcinoma: showed that cholesterol synthase CYP51A1 was significantly upregulated in the lapatinib-resistant lung cancer cells; CYP51A1 inhibitor ketoconazole reduced mitochondrial cholesterol and thereby overcome lapatinib resistance (17).